Sensitization is a non-associative learning process in which repeated administration of a stimulus results in the progressive amplification of a response. Sensitization often is characterized by an enhancement of response to a whole class of stimuli in addition to the one that is repeated. For example, repetition of a painful stimulus may make one more responsive to a loud noise.
Eric Kandel was one of the first to study the neural basis of sensitization, conducting experiments in the 1960s and 1970s on the gill withdrawal reflex of the seaslug Aplysia. Kandel and his colleagues first habituated the reflex, weakening the response by repeatedly touching the animal's siphon. They then paired noxious electrical stimulus to the tail with a touch to the siphon, causing the gill withdrawal response to reappear. After this sensitization, a light touch to the siphon alone produced a strong gill withdrawal response, and this sensitization effect lasted for several days. (After Squire and Kandel, 1999). In 2000, Eric Kandel was awarded the Nobel Prize in Physiology or Medicine for his research in neuronal learning processes.
Neural substrates of sensitizationEdit
|Addiction and dependence glossary|
The neural basis of behavioral sensitization is often not known, but it typically seems to result from a cellular receptor becoming more likely to respond to a stimulus. Several examples of neural sensitization include:
- Electrical or chemical stimulation of the rat hippocampus causes strengthening of synaptic signals, a process known as long-term potentiation or LTP. LTP of AMPA receptors is a potential mechanism underlying memory and learning in the brain.
- In "kindling", repeated stimulation of hippocampal or amygdaloid neurons in the limbic system eventually leads to seizures in laboratory animals. After sensitization, very little stimulation may be required to produce seizures. Thus, kindling has been suggested as a model for temporal lobe epilepsy in humans, where stimulation of a repetitive type (flickering lights for instance) can cause epileptic seizures. Often, people suffering from temporal lobe epilepsy report symptoms of negative effects such as anxiety and depression that might result from limbic dysfunction.
- In "central sensitization," nociceptive neurons in the dorsal horns of the spinal cord become sensitized by peripheral tissue damage or inflammation. This type of sensitization has been suggested as a possible causal mechanism for chronic pain conditions. The changes of central sensitization occur after repeated trials to pain. Research from animals has consistently shown that when a trial is repeatedly exposed to a painful stimulus, the animal’s pain threshold will change and result in a stronger pain response. Researchers believe that there are parallels that can be drawn between these animal trials and persistent pain in people. For example, after a back surgery that removed a herniated disc from causing a pinched nerve, the patient may still continue to “feel” pain. Also, newborns who are circumcised without anesthesia have shown tendencies to react more greatly to future injections, vaccinations, and other similar procedures. The responses of these children are an increase in crying and a greater hemodynamic response (tachycardia and tachypnea).
- Drug sensitization occurs in drug addiction, and is defined as an increased effect of drug following repeated doses (the opposite of drug tolerance). Such sensitization involves changes in brain mesolimbic dopamine transmission, as well as a protein inside mesolimbic neurons called delta FosB. An associative process may contribute to addiction, for environmental stimuli associated with drug taking may increase craving. This process may increase the risk for relapse in addicts attempting to quit.
- Allergic Sensitization – There is an acute response (early stages) and a late-phase response (later stages). In the early stages, the Antigen-Presenting Cell causes a response in a TH2 lymphocyte which produce the cytokine interleukin-4 (IL-4). The TH2 lymphocytes interact with B cells and together they produce IgE. IgE circulates around and binds to receptors of cells leading to an acute inflammatory response. In this case, sensitization is commonly referring to commencement of allergic responses. Allergic sensitization development varies with age, with younger children at the greatest risk of developing allergic sensitization. There are a variety of tests to diagnose allergic conditions. Tests that are commonly used place potential allergens on the skin of the patient and looking for a reaction to look for an allergen-specific IgE (Immunoglobulin E). They have shown that IgE levels are at their greatest before 10 years of age and fall vastly until one reaches 30. There is a school of thought that believes that there are different genetic loci for different ethnicities for the same inflammatory disease. By this thought, asthma has different chromosomal locations in people of European, Hispanic, Asian, and African descent.
Cross-sensitization is a phenomenon in which sensitization to a stimulus is generalized to a related stimulus, resulting in the amplification of a particular response to both the original stimulus and the related stimulus. For example, cross-sensitization to the neural and behavioral effects of addictive drugs are well characterized, such as sensitization to the locomotor response of a stimulant resulting in cross-sensitization to the motor-activating effects of other stimulants. Similarly, reward sensitization to a particular addictive drug often results in reward cross-sensitization, which entails sensitization to the rewarding property of other addictive drugs in the same drug class or even certain natural rewards.
As a causal factor in pathologyEdit
Sensitization has been implied as a causal or maintaining mechanism in a wide range of apparently unrelated pathologies including addiction, allergies, asthma, and some medically unexplained syndromes such as fibromyalgia and multiple chemical sensitivity. Sensitization may also contribute to psychological disorders such as post-traumatic stress disorder, panic anxiety and mood disorders.
- Shettleworth, S. J. (2010). Cognition, Evolution and Behavior (2nd ed.). New York: Oxford.
- Squire LR, Kandel ER (1999). Memory: From Mind to Molecules. New York: Scientific American Library; New York: W.H. Freeman. ISBN 0-7167-6037-1.
- Nestler EJ (December 2013). "Cellular basis of memory for addiction". Dialogues Clin. Neurosci. 15 (4): 431–443. PMC . PMID 24459410.
Despite the importance of numerous psychosocial factors, at its core, drug addiction involves a biological process: the ability of repeated exposure to a drug of abuse to induce changes in a vulnerable brain that drive the compulsive seeking and taking of drugs, and loss of control over drug use, that define a state of addiction. ... A large body of literature has demonstrated that such ΔFosB induction in D1-type [nucleus accumbens] neurons increases an animal's sensitivity to drug as well as natural rewards and promotes drug self-administration, presumably through a process of positive reinforcement ... Another ΔFosB target is cFos: as ΔFosB accumulates with repeated drug exposure it represses c-Fos and contributes to the molecular switch whereby ΔFosB is selectively induced in the chronic drug-treated state.41. ... Moreover, there is increasing evidence that, despite a range of genetic risks for addiction across the population, exposure to sufficiently high doses of a drug for long periods of time can transform someone who has relatively lower genetic loading into an addict.
- Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 364–375. ISBN 9780071481274.
- "Glossary of Terms". Mount Sinai School of Medicine. Department of Neuroscience. Retrieved 9 February 2015.
- Volkow ND, Koob GF, McLellan AT (January 2016). "Neurobiologic Advances from the Brain Disease Model of Addiction". N. Engl. J. Med. 374 (4): 363–371. doi:10.1056/NEJMra1511480. PMID 26816013.
Substance-use disorder: A diagnostic term in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) referring to recurrent use of alcohol or other drugs that causes clinically and functionally significant impairment, such as health problems, disability, and failure to meet major responsibilities at work, school, or home. Depending on the level of severity, this disorder is classified as mild, moderate, or severe.
Addiction: A term used to indicate the most severe, chronic stage of substance-use disorder, in which there is a substantial loss of self-control, as indicated by compulsive drug taking despite the desire to stop taking the drug. In the DSM-5, the term addiction is synonymous with the classification of severe substance-use disorder.
- Collingridge GL, Isaac JT, Wang YT (2004). "Receptor trafficking and synaptic plasticity". Nat Rev Neurosci 5(12): 952–962, PMID 15550950, doi:10.1038/nrn1556.
- Morimoto K, Fahnestock M, Racine RJ (2004). "Kindling and status epilepticus models of epilepsy: Rewiring the brain". Prog Neurobiol 73(1): 1–60, PMID 15193778, doi:10.1016/j.pneurobio.2004.03.009.
- Teicher MH, Glod CA, Surrey J, Swett C, Jr (1993). "Early childhood abuse and limbic system ratings in adult psychiatric outpatients". J Neuropsychiatry Clin Neurosci 5(3): 301–306, PMID 8369640.
- Ji RR, Kohno T, Moore KA, Woolf CJ (2003). "Central sensitization and LTP: Do pain and memory share similar mechanisms?". Trends Neurosci 26(12): 696–705, PMID 14624855.
- Gudin J. (2004). Medscape Neurobiology: Expanding Our Understanding of Central Sensitization. Medscape: Medscape Education.
- Robinson TE, Berridge KC (1993). "The neural basis of drug craving: An incentive-sensitization theory of addiction". Brain Res Brain Res Rev 18(3): 247–291, PMID 8401595.
- Janeway, Charles; Paul Travers, Mark Walport, and Mark Shlomchik (2001). Immunobiology; Fifth Edition. New York and London: Garland Science. pp. e–book. ISBN 978-0-8153-4101-7.
- Janeway C, Travers P, Walport M, Shlomchik M, eds. (2001). Immunobiology 5: The Immune System in Health and Disease. New York: Garland Pub., ISBN 0-8153-3642-X
- Croner S (1992). "Prediction and detection of allergy development: influence of genetic and environmental factors". J. Pediatr. 121 (5 Pt 2): S58–63. doi:10.1016/S0022-3476(05)81408-8. PMID 1447635.
- De Swert LF (1999). "Risk factors for allergy". Eur. J. Pediatr. 158 (2): 89–94. doi:10.1007/s004310051024. PMID 10048601.
- Barnes KC, Grant AV, Hansel NN, Gao P, Dunston GM (2007). "African Americans with asthma: genetic insights". Proc Am Thorac Soc 4 (1): 58–68. doi:10.1513/pats.200607-146JG. PMC 2647616. PMID 17202293. Archived from the original on 2010-11-16.
- Rosen JB, Schulkin J (1998). "From normal fear to pathological anxiety". Psychol Rev 105(2): 325–350, doi:10.1037/0033-295X.105.2.325 PMID 9577241.
- Antelman SM (1988). "Time-dependent sensitization as the cornerstone for a new approach to pharmacotherapy: drugs as foreign/stressful stimuli". Drug Development Research 14: 1–30.
- Post RM (1992). "Transduction of psychosocial stress into the neurobiology of recurrent affective disorder". Am J Psychiatry 149(8): 999–1010, PMID 1353322.